Clinical

Articles

 Tivozanib is approved by the FDA for the treatment of adult patients with relapsed or refractory advanced  renal cell carcinoma who have received 2 or more prior systemic therapies.

Tivozanib added to NCCN guidelines for renal cell carcinoma

Videos

Michael E. Hurwitz, MD, PhD, discusses how immune checkpoint inhibitors have transformed the first-line setting in advanced renal cell carcinoma.



Immunotherapy revolutionizes frontline treatment in advanced RCC

 Tivozanib is approved by the FDA for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma who have received 2 or more prior systemic therapies.

Tivozanib officially launched in US kidney cancer market

The FDA is scheduled to decide on the new drug application by September 15, 2021. 

FDA grants priority review to belzutifan for VHL-associated RCC

Following the recent FDA approval of tivozanib in renal cell carcinoma (RCC), the VEGF-TKI is now being explored in combination with the PD-1 inhibitor nivolumab in the phase 3 TiNivo-2 trial in patients with relapsed/refractory RCC.

Nivolumab plus tivozanib explored in phase 3 kidney cancer trial

The FDA has approved tivozanib for kidney cancer.

FDA approves tivozanib for kidney cancer 

The combination regimen shrank tumors and led to disease control in the majority of patients.

Combo of belzutifan plus cabozantinib active in advanced kidney cancer

An expert panel discusses the case of a 65-year-old Caucasian male who is noted to have an incidental 3-cm right renal mass, enhancing on a contrasted CT scan as part of a routine follow-up for his metastatic castration-resistant prostate cancer, diagnosed in 2017 and currently undergoing therapy.

Case review: An incidentally discovered renal mass

The European Commission is reviewing data from the pivotal phase 3 CheckMate-9ER trial.

Nivolumab/cabozantinib combo nears EU approval for frontline kidney cancer

Adding the off-the-shelf, cell-based immunotherapy ilixadencel to frontline sunitinib was associated with an overall survival benefit in patients with metastatic renal cell carcinoma.

Kidney Cancer